clesacostat/ervogastat (PF-07055341) / Pfizer - LARVOL DELTA

Effect of Varying Degrees of Hepatic Impairment on the Pharmacokinetics of Ervogastat, a Diacylglycerol Acyltransferase 2 (DGAT2) Inhibitor, and Clesacostat, an Acetyl-CoA Carboxylase (ACC) Inhibitor. (PubMed, J Clin Pharmacol) - P1 | "Taking into consideration the safety margins at the highest doses evaluated in Phase 2, no dose adjustment of ervogastat or clesacostat is currently warranted for patients with hepatic impairment. NCT: NCT04091061, NCT03309202."

Journal • PK/PD data • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis

Pfizer and PF-05221304 in NASH: The lead clinical asset (SeekingAlpha) - “The top-line data readout for the Phase 2a monotherapy NAFLD and NASH trial is expected in late Q2/2019.”

P2a data